698
Views
0
CrossRef citations to date
0
Altmetric
Novel Vaccines

Design and evaluation of mRNA encoding recombinant neutralizing antibodies for botulinum neurotoxin type B intoxication prophylaxis

, , , , , , , & show all
Article: 2358570 | Received 07 Mar 2024, Accepted 18 May 2024, Published online: 09 Jun 2024

References

  • Popoff MR, Bouvet P. Genetic characteristics of toxigenic Clostridia and toxin gene evolution. Toxicon 2013;75:63–8. doi:10.1016/j.toxicon.2013.05.003.
  • Hill KK, Smith TJ. Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr Top Microbiol Immunol. 2013;364:1–20. doi:10.1007/978-3-642-33570-9_1.
  • Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69(2):200–35. doi:10.1124/pr.116.012658.
  • Rossetto O, Montecucco C. Tables of toxicity of botulinum and tetanus neurotoxins. Toxins 2019;11(12):686. doi:10.3390/toxins11120686.
  • Dutta SR, Passi D, Singh M, Singh P, Sharma S, Sharma A. Botulinum toxin the poison that heals: a brief review. Natl J Maxillofac Surg. 2016;7(1):10–16. doi:10.4103/0975-5950.196133.
  • Johnson EA, Montecucco C:. Botulism. Handb Clin Neurol. 2008;91:333–68. doi:10.1016/s0072-9752(07)01511-4.
  • Cherington M. Clinical spectrum of botulism. Muscle Nerve. 1998;21(6):701–10. doi:10.1002/(sici)1097-4598(199806)21:6<701:aid-mus1>3.0.co;2-b.
  • Godakova SA, Noskov AN, Vinogradova ID, Ugriumova GA, Solovyev AI, Esmagambetov IB, Tukhvatulin AI, Logunov DY, Naroditsky BS, Shcheblyakov DV. et al. Camelid VHHs fused to human Fc fragments provide long term protection against botulinum neurotoxin a in mice. Toxins 2019;11(8):464. doi:10.3390/toxins11080464.
  • Thran M, Mukherjee J, Pönisch M, Fiedler K, Thess A, Mui BL, Hope MJ, Tam YK, Horscroft N, Heidenreich R. et al. mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol Med. 2017;9(10):1434–47. doi:10.15252/emmm.201707678.
  • Dezfulian M, Hatheway CL, Yolken RH, Bartlett JG. Enzyme-linked immunosorbent assay for detection of Clostridium botulinum type a and type B toxins in stool samples of infants with botulism. J Clin Microbiol. 1984;20(3):379–83. doi:10.1128/jcm.20.3.379-383.1984.
  • Tacket CO, Shandera WX, Mann JM, Hargrett NT. Blake PA: equine antitoxin use and other factors that predict outcome in type a foodborne botulism. Am J Med. 1984;76(5):794–8. doi:10.1016/0002-9343(84)90988-4.
  • Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990;247(4949 Pt 1):1465–8. doi:10.1126/science.1690918.
  • Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202–21. doi:10.1016/j.cmi.2021.10.005.
  • Schlake T, Thran M, Fiedler K, Heidenreich R, Petsch B, Fotin-Mleczek M. mRNA: a novel avenue to antibody therapy? Mol Ther. 2019;27(4):773–84. doi:10.1016/j.ymthe.2019.03.002.
  • Karikó K. In vitro-transcribed mRNA therapeutics: out of the shadows and into the spotlight. Mol Ther. 2019;27(4):691–2. doi:10.1016/j.ymthe.2019.03.009.
  • Mukherjee J, Ondeck CA, Tremblay JM, Archer J, Debatis M, Foss A, Awata J, Erasmus JH, McNutt PM, Shoemaker CB. Intramuscular delivery of formulated RNA encoding six linked nanobodies is highly protective for exposures to three botulinum neurotoxin serotypes. Sci Rep. 2022;12(1):11664. doi:10.1038/s41598-022-15876-2.
  • Jiang Y, Wang R, Guo J, Cheng K, Chen L, Wang X, Li Y, Du P, Gao C, Lu J. Isolation and characterization of Hc-targeting chimeric heavy chain antibodies neutralizing botulinum neurotoxin type B. Front Immunol. 2024;15:1380694. doi:10.3389/fimmu.2024.1380694.
  • Sample PJ, Wang B, Reid DW, Presnyak V, McFadyen IJ, Morris DR, Seelig G. Human 5′ UTR design and variant effect prediction from a massively parallel translation assay. Nat Biotechnol. 2019;37(7):803–9. doi:10.1038/s41587-019-0164-5.
  • Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ. et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020;383(20):1920–31. doi:10.1056/NEJMoa2022483.
  • Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23(5):265–80. doi:10.1038/s41576-021-00439-4.
  • Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20(11):817–38. doi:10.1038/s41573-021-00283-5.
  • Alfagih IM, Aldosari B, AlQuadeib B, Almurshedi A, Alfagih MM. Nanoparticles as adjuvants and nanodelivery systems for mRNA-based vaccines. Pharmaceutics 2020;13(1):45. doi:10.3390/pharmaceutics13010045.
  • Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun. 2018;9(1):2629. doi:10.1038/s41467-018-05096-6.
  • Erasmus JH, Archer J, Fuerte-Stone J, Khandhar AP, Voigt E, Granger B, Bombardi RG, Govero J, Tan Q, Durnell LA. et al. Intramuscular delivery of replicon RNA encoding ZIKV-117 human monoclonal antibody protects against Zika virus infection. Mol Ther Methods Clin Dev. 2020;18:402–14. doi:10.1016/j.omtm.2020.06.011.